Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 +0.67%68 Gross Margin % is 73.68% as of Mar. 2026, which is 2% below its 10-year median of 75.15. GuruFocus rates BOM:543960 with a GF Score™ of 68/100 and a GF Value™ of ₹1,666.31 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 732 Biotechnology companies, Concord Biotech ranks better than 68.58% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Concord Biotech had a gross margin of 73.68% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Concord Biotech Gross Margin % Related Terms
Concord Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Concord Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Concord Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Concord Biotech (BOM:543960) has a Gross Margin % of 73.68% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Concord Biotech and its competitors. This is near median its historical median of 75.15. Over the past decade, Concord Biotech's Gross Margin % has ranged from 72.41 to 80.08. According to the industry distribution chart, Concord Biotech ranks #230 out of 732 companies in the Biotechnology industry, placing it in the top 31.4%.
Is Concord Biotech's Gross Margin % too high?
Concord Biotech's current Gross Margin % of 73.68% is near median its 10-year median of 75.15. Over the past 10 years, this metric has ranged from a low of 72.41 to a high of 80.08. The Biotechnology industry median Gross Margin % is 60.92. Concord Biotech's value of 73.68% is 21% above this industry median. Based on the distribution chart, Concord Biotech ranks #230 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Concord Biotech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #230 out of 732 companies for Gross Margin %. This puts Concord Biotech in the upper half of its industry. The industry median Gross Margin % is 60.92. Concord Biotech's value of 73.68% is 21% above this benchmark. Historically, Concord Biotech's own Gross Margin % has ranged from 72.41 to 80.08 over the past decade. While the company's 10-year median is 75.15 vs. the industry median of 60.92, Concord Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Biotech's current Gross Margin % of 73.68% is 21% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current Gross Margin % is 73.68%, which is near median its own 10-year median of 75.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,666.31, compared to a current price of ₹1,257.00 — trading 24.6% below its estimated fair value. The current Gross Margin % is 73.68%, which is near median its 10-year median of 75.15 and 21% above the Biotechnology industry median of 60.92. Concord Biotech's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Gross Margin % is 73.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,257.00 is trading 24.6% below its estimated GF Value™ of ₹1,666.31.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
Gross Margin %: 73.68% (near median its 10-year median of 75.15)
GF Value™: ₹1,666.31 vs. price of ₹1,257.00 (24.6% below fair value)
Industry Position: 21% above the Biotechnology median (#230 of 732)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score
Get the complete analysis for BOM:543960
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
